IRCT20220122053789N1
Not yet recruiting
Phase 2
Evaluation of the efficacy, safety and reliability of the effect of microneedling with tranexamic acid, in combination with a hydroquinone topical formula, in comparison with any of the treatments alone in patients with melasma: A randomized controlled clinical trial
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Iran University of Medical Sciences
- Enrollment
- 50
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 18 to 60 years old
- •Clinical diagnosis of bilateral melasma of the cheek
Exclusion Criteria
- •Patients who have received any treatment for melasma in the past 1 month.
- •Patients who have contraindications to tranexamic acid. (Includes known drug allergy, intracranial hemorrhage, known color vision disorder, history of arterial or venous thromboembolism or active thromboembolic disease, ischemic heart disease, and stroke)
- •Patients with mental instability (which is expected to affect the study process).
- •Patients who do not have informed consent to participate in the study.
- •Patients who do not have the opportunity to visit regularly and cooperate for scoring and follow\-up sessions.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study of aquatic physiotherapy in women after surgery for breast cancerRBR-4chsdrBrazilian Mastology Research Network
Active, not recruiting
Phase 1
Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19).The study population will consist of adults (18-80 years old) hospitalised for =48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test positive from nasopharyngeal swab. Patients with ARDS or patients requiring mechanical ventilation at screening or randomisation will be excludedMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-002295-13-FRAssistance Publique - Hôpitaux Paris100
Unknown
Phase 3
Difluprednate 0.05% versus Prednisolone acetate 1% eye drops following phacoemulsification surgeryEye DiseasesPACTR202207762785564Suez Canal University Hospital800
Active, not recruiting
Not Applicable
Evaluation of efficacy, acceptability and safety of two different solutions of PEG for colonoscopy in children: a prospective randomized trial. - Different PEG solutions for colonoscopy in childreEUCTR2008-003244-11-ITISTITUTO PER L`INFANZIA BURLO GAROFOLO
Active, not recruiting
Phase 1
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12